Oruka Therapeutics, Inc. ORKA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

MoonLake ImmunotherapeuticsMLTX

$1.79M-30.7%

Kymera TherapeuticsKYMR

$76.14M-6.7%

Alumis Inc.ALMS

$35.66M+1,881%

Avalo TherapeuticsAVTX

$242K-64.4%

Inhibrx Biosciences, Inc.INBX

$5.9M-25.0%

Aclaris TherapeuticsACRS

$1.85M-21.8%

FAQ

What is Oruka Therapeutics, Inc.'s operating lease liabilities (total)?

Oruka Therapeutics, Inc. (ORKA) reported operating lease liabilities (total) of $1.81M in Q1 2026.

How has Oruka Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?

Oruka Therapeutics, Inc.'s operating lease liabilities (total) increased by 90.8% year-over-year, from $947K to $1.81M.

What is the long-term trend for Oruka Therapeutics, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s operating lease liabilities (total) has grown at a 33.8% compound annual growth rate (CAGR), from $450K to $1.93M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.